Cencora said revenue for the Q4 quarter of fiscal 2025 ended September 30 increased 5.9% to $83.7 billion, GAAP diluted earnings per share was $(1.75), and adjusted diluted earnings per share was $3.84.

1. 01

   Cencora said revenue for the Q4 quarter of fiscal 2025 ended September 30 increased 5.9% to $83.7 billion, GAAP diluted earnings per share was $(1.75), and adjusted diluted earnings per share was $3.84.

2. 02

   The company said operating expenses for the Q4 quarter increased 24.1% to $2.9 billion, citing a goodwill impairment charge related to PharmaLex of $723.9 million compared to $418.0 million in the prior year quarter. Operating income was $18.5 million.

3. 03

   Cencora said full-year 2025 revenue increased 9.3% to $321.3 billion, GAAP diluted earnings per share was $7.96, and adjusted diluted earnings per share was $16.00 compared to $13.76 in the prior year.

4. 04

   The company provided fiscal 2026 adjusted diluted earnings per share guidance of $17.45 to $17.75. It also said it raised its quarterly dividend to $0.60 per share from $0.55, a 9% increase.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the opening part of the filing body and confirmed exhibits, within a length limit. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.